Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 19;111(14):2170-2183.e6.
doi: 10.1016/j.neuron.2023.04.020. Epub 2023 May 15.

Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain

Affiliations
Free article

Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain

Martí Colom-Cadena et al. Neuron. .
Free article

Abstract

In Alzheimer's disease, fibrillar tau pathology accumulates and spreads through the brain and synapses are lost. Evidence from mouse models indicates that tau spreads trans-synaptically from pre- to postsynapses and that oligomeric tau is synaptotoxic, but data on synaptic tau in human brain are scarce. Here we used sub-diffraction-limit microscopy to study synaptic tau accumulation in postmortem temporal and occipital cortices of human Alzheimer's and control donors. Oligomeric tau is present in pre- and postsynaptic terminals, even in areas without abundant fibrillar tau deposition. Furthermore, there is a higher proportion of oligomeric tau compared with phosphorylated or misfolded tau found at synaptic terminals. These data suggest that accumulation of oligomeric tau in synapses is an early event in pathogenesis and that tau pathology may progress through the brain via trans-synaptic spread in human disease. Thus, specifically reducing oligomeric tau at synapses may be a promising therapeutic strategy for Alzheimer's disease.

Keywords: Alzheimer; synapse; tau.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests T.S.-J. is on the Scientific Advisory Board of Cognition Therapeutics and has received honoraria for talks for industry collaborators. They did not have any involvement in or influence over the current paper. T.S.-J. is also a member of the Neuron Editorial Advisory Board.

Comment in

Publication types

LinkOut - more resources